tru Independence’s Novavax NVAX Stock Holding History

tru Independence’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-181	Closed	-$20.2K	–	570
2020 Q4	$20.2K	Buy	+181	New	+$19.2K	0.04%	184

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

tru Independence's NVAX Position: Q1 2021 in Review

tru Independence sold out of Novavax (NVAX) in Q1 2021, closing a stake of 181 shares — an estimated $20.2K sold.

tru Independence first reported a position in NVAX in Q4 2020 and held it in 1 quarter. The position peaked at $20.2K in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

tru Independence reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
tru Independence sold 181 Novavax shares in Q1 2021, an estimated $20.2K.
tru Independence first reported a position in Novavax in Q4 2020 and held it in 1 quarter.
tru Independence's Novavax position peaked at $20.2K in Q4 2020.
389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.